Fairfax Station, VA, United States of America

Douglas K Price

This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2018.

USPTO Granted Patents = 1 


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Douglas K. Price: Innovator in Prostate Cancer Prognostics

Introduction

Douglas K. Price is a notable inventor based in Fairfax Station, VA (US). He has made significant contributions to the field of medical research, particularly in the area of prostate cancer. His work focuses on improving prognostic predictions and medical outcomes for patients suffering from this disease.

Latest Patents

Douglas K. Price holds a patent related to the SLCO1B3 genotype. This invention pertains to methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen-independent prostate cancer. It also includes methods for determining and exploiting such differences to enhance medical outcomes. Furthermore, his patent provides methods for determining if a subject has prostate cancer.

Career Highlights

Douglas K. Price is associated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work has been instrumental in advancing the understanding of prostate cancer and improving patient care.

Collaborations

Some of his notable coworkers include Akinobu Hamada and William Douglas Figg. Their collaborative efforts have contributed to the advancements in cancer research and treatment methodologies.

Conclusion

Douglas K. Price's innovative work in the field of prostate cancer prognostics exemplifies the impact of research on improving patient outcomes. His contributions continue to influence the medical community and enhance the understanding of cancer treatment.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…